European House Dust Mite (Der p 23) IgE

If you have ongoing nasal congestion, asthma flares, or stubborn eczema and a standard dust mite test came back unremarkable, you may still be reacting to mites. Der p 23 is a major dust mite allergen that is found both lining the inside of the mite's gut and on the surface of its fecal pellets, and it does not always make it into the extracts used in routine allergy testing. That means a single negative whole-mite result does not always settle the question.

This test measures IgE (immunoglobulin E, an antibody made by your immune system) directed specifically at the Der p 23 protein from Dermatophagoides pteronyssinus, the European house dust mite. The result reflects whether your immune system has been trained to react to one of the most clinically important mite allergens, and it can fill in gaps that whole-extract testing leaves behind.

What Der p 23 Actually Is

Der p 23 is a protein from house dust mite droppings, classed as a major allergen because it triggers IgE in roughly 60 to 74 percent of mite-allergic people across published cohorts. Unlike the better-known dust mite proteins Der p 1 and Der p 2, Der p 23 is tightly bound to fecal particles and is poorly released into the water-based extracts used in standard allergy tests, which is why it can be underrepresented on routine panels.

When this antibody is present in your blood, it means your immune system has gone through allergic sensitization, a process where it has switched its response toward attacking mite particles instead of ignoring them. The test does not measure how many mites are in your home. It measures how strongly your body has been programmed to react to them.

Asthma Risk

Of all the conditions linked to Der p 23 IgE, asthma is the most consistent. Asthmatic children with mite allergy show a wider range of mite IgE responses and higher specific IgE levels than non-asthmatic atopic children. In a German birth cohort, children who developed IgE to Der p 23 or Der p 1 by age five had a higher risk of school-age asthma than children who did not.

Even more striking, some children develop asthma or rhinitis with Der p 23 as their only detectable mite allergen, meaning they would be missed if testing relied solely on Der p 1 and Der p 2. In an East China study of children, lower Der p 23 IgE was seen in those with well-controlled asthma, while higher levels appeared in partially or poorly controlled disease.

Allergic Rhinitis

Der p 23 IgE is common in people with year-round nasal allergy symptoms driven by dust mites. In a real-life multicenter Italian study of 519 mite-allergic patients, about 60 percent had detectable Der p 23 IgE. The proportion of people sensitized only to Der p 23 was small: that study reported around 8 percent, while larger and more recent cohorts have found rates closer to 2 to 4 percent. In Japanese and North Chinese adults with allergic rhinitis, sensitization rates ran from roughly 60 to 72 percent, and Der p 23 positivity was higher in younger patients than in older ones.

Symptom severity scores in some cohorts do not closely track Der p 23 IgE levels, so a number alone does not predict how miserable your nose will feel. What it does tell you is whether mites belong on the short list of triggers worth controlling at home.

Atopic Dermatitis

Der p 23 sensitization is exceptionally common in moderate to severe eczema. In a study of severe atopic dermatitis patients with a Th2-driven immune pattern (a type of allergic inflammation), Der p 23 IgE was detected in about 97.5 percent. This finding comes from a small, selected group of severe Th2-endotype patients and should not be generalized to every person with eczema, but in this subset the molecule appears to dominate the IgE response, which is one reason allergists increasingly include it in detailed component panels for difficult eczema.

When dupilumab, a biologic medication used in severe eczema, was given for 52 weeks, total IgE and Der p 23-specific IgE both dropped meaningfully. That is one of the clearest examples in the literature of an active eczema treatment lowering this specific antibody.

Why a Negative Standard Test Does Not Rule This Out

This is the most actionable point in the entire test. Extract-based skin prick tests and whole-mite IgE tests can underrepresent Der p 23 because the protein does not extract well into the testing liquid. A study using extract-based ImmunoCAPs (a common laboratory testing platform) found that whole-mite IgE was underestimated compared with molecular component testing that included Der p 23.

In some children with clear mite-related symptoms, IgE was found only against Der p 23, with no IgE to Der p 1 or Der p 2 and sometimes higher Der p 23 IgE than the whole-mite reading. If you have classic dust mite symptoms but a normal standard panel, this is the test that may explain the gap.

What a High Result Suggests

A high Der p 23 IgE means your immune system is primed to react to a major component of house dust mite droppings. High readings tend to cluster with IgE to Der p 1 and Der p 2 and with broader polysensitization across multiple mite proteins. They are more commonly seen alongside current asthma, allergic rhinitis, and moderate to severe atopic dermatitis.

A high number does not mean every symptom you have comes from mites. It means mites are a confirmed trigger that deserves serious household control measures and, in many cases, a conversation about allergen immunotherapy.

What a Low or Absent Result Suggests

A low or undetectable Der p 23 IgE does not rule out dust mite allergy. A subset of mite-allergic people produce IgE against other mite proteins instead, such as Der p 1, Der p 2, Der p 5, Der p 7, Der p 10, or Der p 21. For people with confirmed asthma, lower Der p 23 IgE has been linked with better asthma control in some cohorts, suggesting milder Der p 23-driven disease.

If you remain symptomatic with a low Der p 23 result, broader component testing or an allergist evaluation is the next reasonable step.

How Age Shapes Your Result

Der p 23 sensitization is heavily age-dependent. Prevalence peaks in late childhood and then declines toward young adulthood. In the Italian multicenter cohort, the prevalence dropped from 73 percent in the youngest age group to 35 percent in the oldest. Adults who first test positive in their 30s or 40s often have lower readings than children with similar symptoms.

This is why a single value should always be read alongside your age and clinical picture, not as a fixed score.

Why One Reading Is Not Enough

Allergen-specific IgE levels respond over months and years to allergen exposure and to treatments such as allergen immunotherapy. A single result tells you whether you are sensitized today. A trend tells you whether your sensitization is intensifying, holding steady, or fading with mitigation efforts and treatment.

If you are starting house dust mite immunotherapy or aggressive home control measures, a baseline reading followed by a follow-up roughly 6 to 12 months later, and at least annual retesting after that, gives you a clear picture of how your immune system is shifting. There is no strongly evidence-based monitoring interval, since the published studies measured antibodies at varying timepoints, so this cadence is a reasonable rule of thumb rather than a fixed standard. Studies of sublingual and injection-based mite immunotherapy show that Der p 23-specific antibody levels change over time during treatment, although these changes do not perfectly predict who will feel better. The point of trending is not to chase a target number but to see whether your overall mite allergy profile is moving in the right direction.

What to Do With an Unexpected Result

If your Der p 23 IgE is positive and you have asthma, rhinitis, or eczema, the next step is to take dust mite exposure seriously and to discuss formal allergen immunotherapy with an allergist. Tablet-based sublingual immunotherapy for house dust mite has been studied in large trials, and clinical benefit occurred regardless of Der p 23 status, so a positive result does not exclude you from treatment. With subcutaneous (injection) immunotherapy the picture is less settled: in some studies, patients sensitized mainly to Der p 1 and Der p 2 responded better than those with additional IgE specificities, so molecular profile may matter more for shots than for tablets.

If Der p 23 is positive but your standard whole-mite IgE was negative, this finding likely explains your symptoms and should be shared with your clinician. If Der p 23 is negative but you have ongoing mite-pattern symptoms, ask about extended component panels that cover Der p 1, Der p 2, Der p 5, Der p 7, Der p 10, Der p 21, and Der p 23. For severe eczema with positive Der p 23, this is also useful information for allergists considering biologic therapy, since dupilumab has been shown to lower these levels over a year of treatment.

What This Test Cannot Tell You

This is not a measure of mite density in your home, and it is not a measure of how severe a future asthma attack will be. It does not replace lung function testing, eczema severity scoring, or a clinical history. It is one well-validated piece of an allergy workup, particularly valuable when standard whole-mite testing leaves questions unanswered.